CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
基于 KarMMa 试验中接受单次输注 ide-cel 患者 HCRU 数据的成本外推显示，初始治疗后 2 年内 HCRU 和成本大幅降低。
根据 HCRU 数据估算输注后的费用，数据包括医疗机构照护、诊断检查、药物和操作；提取普通住院和重症监护病房（ICU）的住院时长（LOS）。按照试验方案，所有患者输注后住院 14 天。分析纳入在美国接受治疗、使用 ide-cel 靶剂量 450 × 10⁶ CAR⁺ T 细胞的患者，并假设住院时间为 7 天进行情景分析。
共有 128 例患者接受 ide-cel 并纳入分析。平均年龄为 60 岁，59% 为男性，81% 为白人。平均总住院时间为 23.9 天。输注后 24 个月内估算总费用为每位患者 115,614 美元，其中医疗机构费用占 75%（86,385 美元）。大部分费用发生于第一个月（58%；67,259 美元）。假设住院 7 天的情景分析显示，24 个月估算费用为 92,294 美元。54 例（42%）接受 ide-cel 高剂量治疗的患者，24 个月总费用为每位患者 113,298 美元。
根据 KarMMa 试验中接受单次 ide-cel 输注患者的 HCRU 数据进行外推后发现，初始治疗后 2 年内 HCRU 和费用大幅下降。大部分费用发生在 ide-cel 输注后的第一个月，可能与试验方案要求住院 14 天有关。这些发现提示，治疗后即刻的月度照护增量费用不高，而常规临床实践中的费用可能更低。
Post-infusion costs were estimated based on HCRU data, including facility care, diagnostics, medications, and procedures. Length of stay (LOS) was extracted for inpatient and intensive care unit (ICU) care. All patients had a 14-day post-infusion inpatient stay per trial protocol. Analyses were conducted for patients treated in the United States (US), who received the ide-cel target dose of 450 10 6 CAR + T cells and assuming a 7-day inpatient stay.
Overall, 128 patients received ide-cel and were included in this analysis. Mean age was 60 years, 59% were men, and 81% were white. Mean total LOS was 23.9 days. Total estimated costs over 24 months post-infusion were US$115,614 per patient, driven by facility costs (75%; $86,385). Most costs were incurred in the first month (58%; $67,259). The scenario analysis assuming a 7-day inpatient stay showed estimated 24-month costs of $92,294. For the 54 (42%) patients who received ide-cel high dose, total costs over 24 months were $113,298 per patient.
Extrapolation of costs based on HCRU data from patients receiving single-infusion of ide-cel in the KarMMa trial showed substantially reduced HCRU and costs over 2 years after initial treatment. Most costs were incurred during the first month after ide-cel infusion, likely attributable to the 14-day inpatient stay required by the trial protocol. These findings suggest a nominal, incremental monthly cost of care immediately after treatment, which may be lower in routine clinical practice.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
